Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in patients with relapsed or refractory neuroblastoma. Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG toget...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: DuBois, Steven G., Chesler, Louis, Groshen, Susan, Hawkins, Randall, Goodarzian, Fariba, Shimada, Hiroyuki, Yanik, Greg, Tagen, Michael, Stewart, Clinton, Mosse, Yael P., Maris, John M., Tsao-Wei, Denice, Marachelian, Araz, Villablanca, Judith G., Matthay, Katherine K.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6814395/
https://ncbi.nlm.nih.gov/pubmed/22421195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3201
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires